by Sabine Possmann | Dec 16, 2022 | Uncategorized
On 15th December, the SME T-CURX GmbH announced the appointment of Thomas Loeser as the new CFO of the company and the attendance of the JPM 41st Annual Healthcare Conference 2023 in San Francisco from Jan 9-12, 2023.Tom has served for more than 20 years as CFO of...
by Sabine Possmann | Dec 8, 2022 | Uncategorized
Monica Casucci, group leader of the innovative immunotherapies unit at IRCCS Ospedale San Raffaele, was awarded by the European Research Council, to refine her outstanding research work on a novel CAR specific for the CD44v6 antigen and strategies to improve CAR-T...
by Sabine Possmann | Dec 8, 2022 | Uncategorized
This year, the most important scientific price of the BAdW, endowed with 25.000 Euro, was awarded to Michael Hudecek, for his outstanding work on gen-modified CART-T cell therapy for cancer treatment. The Schelling price is awarded bi-annually, for outstanding...
by Sandra Annetzberger | Jul 25, 2022 | Uncategorized
An informative open access article was published on the current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. As one can tell from the article, the number of clincial trials for CAR-T multiple myeloma therapies is still rather low. While...
by Sandra Annetzberger | Jul 15, 2022 | Uncategorized
The 5th digital myeloma forum was a great success. On 9th July, the 5th edition of the Würzburg Myeloma Forum took place. With far more than 200 participants, mostly myeloma patients and their families as well as patient organisations, a large audience learned about...
by Sabine Possmann | Apr 4, 2022 | Uncategorized
VJHemOnc’s video series on CART cells interviewing HErmann Einsele During the EBMT-EHA 4th European CAR T-cell Meeting, VJHemOnc interviewed Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany on CAR-T therapy for multiple myeloma patients and...
